FCRH5-Targeting and Other Emerging Bispecifics in R/R MM

Video

Jeremy Larsen, MD, discusses data from a phase 1/2 study of cevostamab and other emerging bispecifics being evaluated in patients with relapsed/refractory multiple myeloma.

Recent Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
A panel of 4 experts on multiple myeloma
4 KOLs are featured in this program.
Related Content